Trial Profile
Impact of pre-existing substitutions at resistance-associated variants positions on daclatasvir/sofosbuvir combination treatment in patients infected with HCV genotypes (GT) 1a, 1b, 3 and 4.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Apr 2016
Price :
$35
*
At a glance
- Drugs Daclatasvir (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 20 Apr 2016 New trial record
- 25 Feb 2016 Results presented at the 23rd Conference on Retroviruses and Opportunistic Infections